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Haem-dependent dimerization of
PGRMC1/Sigma-2 receptor facilitates
cancer proliferation and chemoresistance
Yasuaki Kabe1,*, Takanori Nakane2,3,*, Ikko Koike1, Tatsuya Yamamoto4, Yuki Sugiura1, Erisa Harada4,
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So Iwata2,6, Yuki Yamaguchi7, Elena Krayukhina8, Masanori Noda8, Hiroshi Handa9, Koichiro Ishimori5,
Susumu Uchiyama8,10, Takuya Kobayashi2,11,12 & Makoto Suematsu13
Progesterone-receptor membrane component 1 (PGRMC1/Sigma-2 receptor) is a
haem-containing protein that interacts with epidermal growth factor receptor (EGFR) and
cytochromes P450 to regulate cancer proliferation and chemoresistance; its structural basis
remains unknown. Here crystallographic analyses of the PGRMC1 cytosolic domain at 1.95Å
resolution reveal that it forms a stable dimer through stacking interactions of two
protruding haem molecules. The haem iron is ﬁve-coordinated by Tyr113, and the open
surface of the haem mediates dimerization. Carbon monoxide (CO) interferes with PGRMC1
dimerization by binding to the sixth coordination site of the haem. Haem-mediated PGRMC1
dimerization is required for interactions with EGFR and cytochromes P450, cancer
proliferation and chemoresistance against anti-cancer drugs; these events are attenuated by
either CO or haem deprivation in cancer cells. This study demonstrates protein dimerization
via haem–haem stacking, which has not been seen in eukaryotes, and provides insights into
its functional signiﬁcance in cancer.
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M
uch attention has been paid to the roles of haem-iron in
cancer development. Increased dietary intake of haem is
a risk factor for several types of cancer1–3. Previous
studies showed that deprivation of iron or haem suppresses
tumourigenesis4,5. On the other hand, carbon monoxide (CO),
the gaseous mediator generated by oxidative degradation of haem
via haem oxygenase (HO), inhibits tumour growth6. Thus, a
tenuous balance between free haem and CO plays key roles in
cancer development and chemoresistance7, although the
underlying mechanisms are not fully understood.
To gain insight into the underlying mechanisms, we took
chemical biological approaches using afﬁnity nanobeads8
carrying haem and identiﬁed progesterone-receptor membrane
component 1 (PGRMC1) as a haem-binding protein from mouse
liver extracts (Supplementary Fig. 1). PGRMC1 is a member of
the membrane-associated progesterone receptor (MAPR) family9
with a cytochrome b5-like haem-binding region, and is known to
be highly expressed in various types of cancers10–17. PGRMC1 is
anchored to the cell membrane through the N-terminal
transmembrane helix and interacts with epidermal growth
factor receptor (EGFR)18 and cytochromes P450 (ref 19). While
PGRMC1 is implicated in cell proliferation and cholesterol
biosynthesis20,21, the structural basis on which PGRMC1 exerts
its function remains largely unknown.
Here we show that PGRMC1 exhibits a unique haem-
dependent dimerization. The dimer binds to EGFR and
cytochromes P450 to enhance tumour cell proliferation and
chemoresistance. The dimer is dissociated to monomers by
physiological levels of CO, suggesting that PGRMC1 serves as a
CO-sensitive molecular switch regulating cancer cell proliferation.
Results
X-ray crystal structure of PGRMC1. We solved the crystal
structure of the haem-bound PGRMC1 cytosolic domain
(a.a.72–195) at 1.95Å resolution (Supplementary Fig. 2).
In the presence of haem, PGRMC1 forms a dimeric structure
largely through hydrophobic interactions between the haem
moieties of two monomers (Fig. 1a, Table 1 and Supplementary
Fig. 3; a stereo-structural image is shown in Supplementary
Fig 4). While the overall fold of PGRMC1 is similar to that of
canonical cytochrome b5, their haem irons are coordinated
differently. In cytochrome b5, the haem iron is six-coordinated
by two axial histidine residues. These histidines are missing
in PGRMC1, and the haem iron is ﬁve-coordinated by
Tyr113 (Y113) alone (Fig. 1b and Supplementary Fig. 3).
A homologous helix that holds haem in cytochrome b5 is longer,
shifts away from haem, and does not form a coordinate bond in
PGRMC1 (Fig. 1c). Consequently, the ﬁve-coordinated haem of
PGRMC1 has an open surface that allows its dimerization
through hydrophobic haem–haem stacking. Contrary to our
ﬁnding, Kaluka et al.22 recently reported that Tyr164 of
PGRMC1 is the axial ligand of haem because mutation of this
residue impairs haem binding. Our structural data revealed
that Tyr164 and a few other residues such as Tyr107 and Lys163
are in fact hydrogen-bonded to haem propionates. This is
consistent with observations by Min et al.23 that Tyr 107 and
Tyr113 of PGRMC1 are involved in binding with haem.
These amino acid residues are conserved among MAPR
family members (Supplementary Fig. 5a), suggesting that these



















Figure 1 | X-ray crystal structure of PGRMC1. (a) Structure of the PGRMC1 dimer formed through stacked haems. Two PGRMC1 subunits (blue and
green ribbons) dimerize via stacking of the haem molecules. (b) Haem coordination of PGRMC1 with Tyr113. Comparison of PGRMC1 (blue) and
cytochrome b5 (yellow, ID: 3NER). (c) PGRMC1 has a longer helix (a.a.147–163), which is shifted away from the haem (arrow).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11030
2 NATURE COMMUNICATIONS | 7:11030 | DOI: 10.1038/ncomms11030 | www.nature.com/naturecommunications
PGRMC1 exhibits haem-dependent dimerization in solution.
In the PGRMC1 crystal, two different types of crystal contacts
(chain A–A00 and A–B) were observed in addition to the haem-
mediated dimer (chain A–A0) (Supplementary Figs 3 and 6a). To
conﬁrm that haem-assisted dimerization of PGRMC1 occurs in
solution, we analysed the structure of apo- and haem-bound
PGMRC1 by two-dimensional nuclear magnetic resonance
(NMR) using heteronuclear single-quantum coherence and
transverse relaxation-optimized spectroscopy (Supplementary
Figs 6b and 7). NMR signals from some amino acid residues of
PGRMC1 disappeared due to the paramagnetic relaxation effect
of haem (Supplementary Figs 6b); these residues were located in
the haem-binding region. When chemical shifts of
apo- and haem-bound forms of PGMRC1 were compared, some
amino acid residues close to those which disappeared because of
the paramagnetic relaxation effect of haem exhibit notable
chemical shifts (Supplementary Fig. 6a,b; dark yellow).
However, at the interfaces of the other possible dimeric structures
(Supplementary Fig. 6a, chain A–A00; cyan and chain A–B; violet),
no signiﬁcant difference was observed. Furthermore, free energy
of dissociation predicted by PISA24 suggested that the haem-
mediated dimer is stable in solution while the other potential
interactions are not. We also attempted to predict
the secondary structure of PGRMC1 through NMR data by
calculating with TALOSþ program25 (Supplementary Fig. 8); the
prediction suggested that the overall secondary structure is
comparable between apo- and haem-bound forms of PGRMC1 in
solution.
We analysed the haem-dependent dimerization of the
PGRMC1 cytosolic domain (a.a.44–195) in solution (Fig. 2 and
Table 2). Mass spectrometry (MS) analyses under non-denaturing
condition demonstrated that the apo-monomer PGRMC1
resulted in dimerization by binding with haem (Fig. 2a).
It should be noted that a disulﬁde bond between two Cys129
residues is observed in the crystal of PGRMC1 (Fig. 1a), while
Cys129 is not conserved among the MAPR family proteins
(Supplementary Fig. 5a). This observation led us to examine
whether or not the disulﬁde bond contributes to PGRMC1
dimerization. MS analyses under non-denaturing conditions
clearly showed that the Cys129Ser (C129S) mutant is dimerized
in the presence of haem, indicating that the haem-mediated
dimerization of PGRMC1 occurs independently of the
disulﬁde bond formation via Cys129 (Fig. 2a). Supporting this,
MS analyses under denaturing conditions showed that
haem-mediated PGRMC1 dimer is completely dissociated into
monomer, indicating that dimerization of this kind is not
mediated by any covalent bond such as disulﬁde bond
(Supplementary Fig. 9).
We also analysed the haem-dependent dimerization of
PGRMC1 by diffusion-ordered NMR spectroscopy (DOSY)
analyses (Table 2, Supplementary Fig. 10). The results suggested
that the hydrodynamic radius of haem-bound PGRMC1 is larger
than that of apo-PGRMC1. To further evaluate changes in
molecular weights in dimerization of PGRMC1, sedimentation
velocity analytical ultracentrifugation (SV-AUC) analysis was
carried out. Whereas the wild-type (wt) apo-PGRMC1 appeared
at a 1.9 S peak as monomer, the haem-binding PGRMC1 was
converted into dimer at a 3.1 S peak (Fig. 2b). Similarly, the
C129S mutant of PGRMC1 converted from monomer to dimer
by binding to haem (Fig. 2b). SV-AUC analyses also allowed us to
examine the stability of haem/PGRMC1 dimer. To this end, we
used different concentrations (3.5–147mmol l 1) of haem-bound
PGRMC1 protein (a.a. 72–195), which were identical to that used
in the crystallographic analysis. The sedimentation coefﬁcients
calculated on the basis of the crystal structure were 1.71 S for
monomer and 2.56 S for dimer (Supplementary Fig. 11, upper
panel). The results showed that the PGRMC1 dimer is not
dissociated into monomer at all concentrations examined
(Supplementary Fig. 11, lower panel), suggesting that the Kd
value of haem-mediated dimer of PGRMC1 is under
3.5 mmol l 1. A value of this kind implies that the PGRMC1
dimer is more stable than other dimers of extracellular domain of
membrane proteins such as Toll like receptor 9 (dimerization
Kd of 20 mmol l 1) (ref. 26) and plexin A2 receptor (dimerization
Kd higher than 300 mmol l 1) (ref. 27). The current analytical
data conﬁrmed that apo-PGRMC1 monomer converts into dimer
by binding to haem in solution (Table 2).
We also showed by haem titration experiments that haem
binding to PGRMC1 was of low afﬁnity with a Kd value of
50 nmol l 1; this is comparable with that of iron regulatory
protein 2, which is known to be regulated by intracellular levels of
haem28 (Fig. 2c and Supplementary Table 1). These results raised
the possibility that the function of PGRMC1 is regulated by
intracellular haem concentrations.
CO inhibits haem-dependent dimerization of PGRMC1.
Crystallographic analyses revealed that Tyr113 of PGRMC1 is an
axial ligand for haem and contributes to haem-dependent
dimerization (Fig. 1a). Analysis of UV-visible spectra revealed
that the heme of PGRMC1 is reducible from ferric to ferrous
state, thus allowing CO binding (Fig. 3a). Furthermore, the UV-
visible spectrum of the wild type PGRMC1 was the
same as that of the C129S mutant of PGRMC1, and the R/Z ratio
determined by the intensities between the Soret band (394 nm)
peak and the 274-nm peak showed that these proteins were fully
loaded with haem (Supplementary Fig. 12). Analysis of the ferric
form of PGRMC1 using resonance Raman spectroscopy
Table 1 | Data collection and reﬁnement statistics.
Native Phasing
Data collection
Space group I4122 I4122
Cell dimensions
a, b, c (Å) 167.23, 167.23, 63.46 168.11, 168.11, 63.65
a, b, g () 90, 90, 90 90, 90, 90





Rmeas 0.067 (1.168) 0.010 (0.850)
I/sI 22.83 (2.39) 22.43 (4.54)
Completeness (%) 97.8 (99.0) 99.1 (97.6)
Multiplicity 11.2 (13.8) 14.9 (15.2)
CC1/2 100 (81.8) 99.9 (93.5)
Reﬁnement
Resolution (Å) 19.72–1.95











Bond lengths (Å) 0.008
Bond angles () 1.164
*Highest resolution shell is shown in parenthesis.
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(Supplementary Fig. 13) showed that the relative intensity of
oxidation and spin state marker bands (n4 and n3) is close to 1.0,
which is consistent with it being a haem protein with a
proximal Tyr coordination29. A speciﬁc Raman shift peaking at
vFe–CO¼ 500 cm 1 demonstrated that the CO-bound haem of
PGRMC1 is six-coordinated (Supplementary Fig. 13).
Since PGRMC1 dimerization involves the open surface of
haem on the opposite side of the axial Tyr113, no space for CO
binding is available in the dimeric structure (Fig. 3b). This
prompted us to ask if CO binding to haem causes dissociation of
the PGRMC1 dimer. Analysis by gel ﬁltration chromatography
revealed that the relative molecular sizes of the wild-type and the
C129S mutant of PGRMC1 are increased by adding haem to apo-
PGRMC1 regardless of the oxidation state of the iron (Fig. 3c),
which is in agreement with the results in Table 1. CO application
to ferrous PGRMC1 abolished the haem-dependent increase in its
molecular size. Under this reducing condition in the presence
of dithionite, analyses of UV-visible spectra indicated that
CO-binding with haem-PGRMC1 is stable, showing only 20%
reduction of the absorbance at 412 nm within 2 h (Supplementary
Fig. 14). Furthermore, the Tyr113Phe (Y113F) mutant of
PGRMC1 was not responsive to haem. These results suggest that
CO favours the six-coordinate form of haem and interferes
with the haem-mediated dimerization of PGRMC1. To examine
the inhibitory effects of CO on haem-mediated PGRMC1
dimerization, SV-AUC analysis was carried out. The peak
corresponding to the haem/PGRMC1 dimer was detected under
reducing conditions in the presence of dithionite (Supplementary
Fig. 15, middle panel). Under these circumstances, CO applica-
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Figure 2 | PGRCM1 is dimerized by binding with haem. (a) Mass spectrometric analyses of the wild-type (wt) PGRMC1 or the C129S mutant in the
presence or absence of haem under non-denaturing condition. Both proteins had identical lengths (a.a.44–195). Data of experimental mass show
mean±s.d. (b) SV-AUC analyses of the wt-PGRMC1 and the C129S mutant (a.a.44–195) in the presence or absence of haem. SV-AUC experiments were
performed with 1.5mgml 1 of PGRMC1 proteins. The major peak with sedimentation coefﬁcient S20,w of 1.9B2.0 S (monomer) or 3.1 S (dimer) was
detected. (c) Difference absorption spectra of PGRMC1 (a.a.44–195) titrated with haem (left panel). The titration curve of haem to PGRMC1 (right panel).
The absorbance difference at 400nm is plotted against the haem concentration.
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PGRMC1 to generate a peak of monomers (Supplementary
Fig. 15, lower panel). These observations raised the transition
model for structural regulation of PGRMC1 in response to haem
(Fig. 3d). As mentioned above, apo-PGRMC1 exists as monomer.
By binding with haem (binding Kd¼ 50 nmol l 1), PGRMC1
forms a stable dimer (dimerization Kdoo3.5 mmol l 1) through
stacking of the two open surfaces of the ﬁve-coordinated haem
molecules in each monomer. CO induces the dissociation of the
haem-mediated dimer of PGRMC1 by interfering with the
haem-stacking interface via formation of the six-coordinated
CO-haem-PGRMC1 complex. Such a dynamic structural
regulation led us to further examine the regulation of PGRMC1
functions in cancer cells.
PGRMC1 dimerization is required for binding to EGFR.
Because PGRMC1 is known to interact with EGFR and to
accelerate tumour progression18, we examined the effect of haem-
dependent dimerization of PGRMC1 on its interaction with
EGFR by using puriﬁed proteins. As shown in Fig. 4a, the
cytosolic domain of wild-type PGRMC1, but not the Y113F
mutant, interacted with puriﬁed EGFR in a haem-dependent
manner. This interaction was disrupted by the ruthenium-based
CO-releasing molecule, CORM3, but not by RuCl3 as a control
reagent (Fig. 4b). We further analysed the intracellular interaction
between PGRMC1 and EGFR. FLAG-tagged PGRMC1
ectopically expressed in human colon cancer HCT116 cells was
immunoprecipitated with anti-FLAG antibody, and co-
immunoprecipitated EGFR and endogenous PGRMC1 binding
to FLAG-PGRMC1 were detected by Western blotting (Fig. 4c).
The C129S mutant of PGRMC1 also interacted with endogenous
PGRMC1 and EGFR (Supplementary Fig. 16). Whereas FLAG-
tagged wild-type PGRMC1 interacted with endogenous PGRMC1
and EGFR, the Y113F mutant did not. We also examined the
effect of succinylacetone (SA), an inhibitor of haem biosynthesis
(Fig. 4d). As expected, SA signiﬁcantly reduced PGRMC1
dimerization and its interaction with EGFR (Fig. 4e), indicating
that haem-mediated dimerization of PGMRC1 is critical for its
binding to EGFR.
PGRMC1 dimer facilitates EGFR-mediated cancer growth.
Next, we investigated the functional signiﬁcance of PGRMC1
dimerization in EGFR signaling. EGF-induced phosphorylations
of EGFR and its downstream targets AKT and ERK were
decreased by PGRMC1 knockdown (PGRMC1-KD) (Fig. 4f).
Similarly, EGFR signaling was suppressed by treatment of
HCT116 cells with SA (Fig. 4g) or CORM3 (Fig. 4h). These
results suggested that haem-mediated dimerization of PGRMC1
is critical for EGFR signaling.
To further investigate the role of the dimerized form of
PGRMC1 in cancer proliferation, we performed PGRMC1
knockdown-rescue experiments using FLAG-tagged wild-type
and Y113F PGRMC1 expression vectors, in which silent
mutations were introduced into the nucleotide sequence targeted
by shRNA (Fig. 5a). While proliferation of HCT116 cells was not
affected by knocking down PGRMC1, PGRMC1-KD cells were
more sensitive to the EGFR inhibitor erlotinib than control
HCT116 cells, and the knockdown effect was reversed by
co-expression of shRNA-resistant wild-type PGRMC1 but not
of the Y113F mutant (Fig. 5b). Chemosensitivity enhancement by
two different shRNAs to PGRMC1 was seen also in HCT116 cells
and human hepatoma HuH7 cells (Supplementary Fig. 17).
Furthermore, PGRMC1-KD inhibited spheroid formation of
HCT116 cells in culture, and this inhibition was reversed by
co-expression of wild-type PGRMC1 but not of the Y113F
mutant (Fig. 5c and Supplementary Fig. 18). Thus, PGRMC1
dimerization is important for cancer cell proliferation and
chemoresistance.
We examined the role of PGRMC1 in metastatic progression
by xenograft transplantation assays using super-immunodeﬁcient
NOD/scid/gnull (NOG) mice7,30,31. Ten days after intra-splenic
implantation of HCT116 cells that were genetically tagged with a
ﬂuorescent protein Venus, the group implanted with PGRMC1-
KD cells showed a signiﬁcant decrease of liver metastasis in
comparison with the control group (Fig. 5d).
Interaction of PGRMC1 dimer with cytochromes P450. Since
PGRMC1 has been shown to interact with cytochromes P450
(ref 19), we investigated whether the haem-mediated
dimerization of PGRMC1 is necessary for their interactions.
Recombinant CYP1A2 and CYP3A4 including a microsomal
formulation containing cytochrome b5 and cytochrome P450
reductase, drug-metabolizing cytochromes P450, interacted with
wild-type PGRMC1, but not with the Y113F mutant, in a haem-
dependent manner (Fig. 6a,b). Moreover, the interaction of
PGRMC1 with CYP1A2 was blocked by CORM3 under reducing
conditions (Fig. 6c), indicating that PGRMC1 dimerization is
Table 2 | PGRMC1 proteins exhibit haem-dependent dimerization in solution.
Apo form Haem-bound form
Mass (Da) Mass (Da)
a PGRMC1 wt (a.a.44–195)
ESI-MS — 17,844.14 — 36,920.19
Theoretical 17,843.65 36,918.06
Hydrodynamic radius 109 (m) MW (kDa) Hydrodynamic radius 10 9 (m) MW (kDa)
DOSY 2.04–2.15 20 2.94–3.02 42
S20,w (S) MW (kDa) S20,w (S) MW (kDa)
SV-AUC 1.9 17.6 3.1 35.5
b PGRMC1 C129S (a.a.44–195)
ESI-MS — 17,827.91 — 36,887.07
Theoretical 17,827.59 36,885.6
S20,w (S) MW (kDa) S20,w (S) MW (kDa)
SV-AUC 2.0 18.1 3.1 35.8
Differences in molecular weights of the wild-type (wt; a) and the C129S mutant (b) PGRMC1 proteins in the absence (apo form) or the presence of haem (haem-bound form). The protein sizes of the wt
and C129S PGRMC1 cytosolic domains (a.a.44–195) in the presence or absence of haem were estimated by ESI-MS, DOSY and SV-AUC.
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necessary for its interaction with cytochromes P450. Doxorubicin
is an anti-cancer reagent that is metabolized into inactive dox-
orubicinol by CYP2D6 and CYP3A4 (Fig. 6d)32,33. PGRMC1-KD
signiﬁcantly suppressed the conversion of doxorubicin to
doxorubicinol (Fig. 6d) and increased sensitivity to doxorubicin
(Fig. 6e). Enhanced doxorubicin sensitivity was modestly but
signiﬁcantly induced by PGRMC1-KD. This effect was reversed
by co-expression of the wild-type PGRMC1 but not of the Y113F
mutant, suggesting that PGRMC1 enhances doxorubicin
resistance of cancer cells by facilitating its degradation via
cytochromes P450. To gain further insight into the interaction
between PGRMC1 and cytochromes P450, surface plasmon
resonance analyses were conducted using recombinant CYP51
and PGRMC1. This was based on a previous study showing that
PGRMC1 binds to CYP51 and enhances cholesterol biosynthesis
by CYP51 (refs 19,34). CYP51 interacted with PGRMC1 in a
concentration-dependent manner in the presence of haem, but
not in its absence (Supplementary Fig. 19), suggesting the
requirement for the haem-dependent dimerization of PGRMC1.
The Kd value of PGRMC1 binding to CYP51 was in a micromolar
range and comparable with those of other haem proteins, such as
cytochrome P450 reductase35 and neuroglobin/Gai1 (ref. 36),
suggesting that haem-dependent PGRMC1 interaction with
CYP51 is biologically relevant.
Discussion
In this study, we showed that PGRMC1 dimerizes by stacking
interactions of haem molecules from each monomer. Recently,
Lucas et al.37 reported that translationally-controlled tumour
protein was dimerized by binding with haem, but its structural
basis remains unclear. This is the report showing crystallographic
evidence that indicates roles of the direct haem–haem stacking in
haem-mediated dimerization in eukaryotes, although a few
b
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Figure 3 | Carbon monoxide inhibits haem-dependent PGRMC1 dimerization. (a) UV-visible absorption spectra of PGRMC1 (a.a.44–195).
Measurements were performed in the presence of the oxidized form of haem (ferric), the reduced form of haem (ferrous) and the reduced form
of haem plus CO gas (ferrousþCO). (b) Close-up view of haem stacking. Spheres are drawn with van der Waals radii. (c) Gel-ﬁltration chromatography
analyses of PGRMC1 (a.a.44–195) wild-type (wt) and the Y113F or C129S mutant in the presence or absence of haem, dithionite and/or CO.
(d) Transition model for structural regulation of PGRMC1 in response to haem and CO.
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examples are known in bacteria38. Sequence alignments show that
haem-binding residues (Tyr113, Tyr107, Lys163 and Tyr164) in
PGRMC1 are conserved among MAPR proteins (Supplementary
Fig. 5). In the current study, the Y113 residue plays a crucial role
for the haem-dependent dimerization of PGRMC1 and resultant
regulation of cancer proliferation and chemoresistance (Figs 5c
and 6e). Since the Y113 residue is involved in the putative
consensus motif of phosphorylation by tyrosine kinases
such as Abl and Lck39, we investigated whether phosphorylated
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Figure 4 | Haem-dependent dimerization of PGRMC1 is necessary for tumour proliferation mediated by EGFR signalling. (a) FLAG-PGRMC1 wild-type
(wt) and Y113F mutant proteins (a.a.44–195), in either apo- or haem-bound form, were incubated with puriﬁed EGFR and co-immunoprecipitated with
anti-FLAG antibody-conjugated beads. Input and bound proteins were detected by Western blotting. (b) In vitro binding assay was performed as in (a)
using haem-bound FLAG-PGRMC1 wt (a.a.44–195) and puriﬁed EGFR with or without treatment of RuCl3 and CORM3. (c) FLAG-PGRMC1 wt or Y113F
(full length) was over-expressed in HCT116 cells and immunoprecipitated with anti-FLAG antibody-conjugated beads. Co-immunoprecipitated proteins
(FLAG-PGRMC1, endogenous PGRMC1 and EGFR) were detected with Western blotting by using anti-PGRMC1 or anti-EGFR antibody. (d) HCT116 cells
were treated with or without 250mmol l 1 of succinylacetone (SA) for 48 h. The intracellular haem was extracted and quantiﬁed by reverse-phase HPLC.
The data represent mean±s.d. of four separate experiments. **Po0.01 using unpaired Student’s t-test. (e) Co-immunoprecipitation assay was performed
as in (c) with or without SA treatment in HCT116 cells. (f) HCT116 cells expressing control shRNA or those knocking down PGRMC1 (PGRMC1-KD) were
treated with EGF or left untreated, and components of the EGFR signaling pathway were detected by Western blotting. (g,h) HCT116 cells were treated with
or without EGF, SA, RuCl3 and CORM3 as indicated, and components of the EGFR signaling pathway were detected by Western blotting.
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however, undetectable under current experimental conditions
(Supplementary Fig. 20). Recently, Peluso et al.40 reported that
PGRMC1 binds to PGRMC2, suggesting that MAPR family
members may also undergo haem-mediated heterodimerization.
We showed that the haem-mediated dimer of PGRMC1
enables interaction with different subclasses of cytochromes
P450 (CYP) (Fig. 6). While the effects of PGRMC1 on cholesterol
synthesis mediated by CYP51 have been well documented in
yeast19,41 and human cells34, it has not been clear whether
drug-metabolizing CYP activities are regulated by PGRMC1.
Szczesna-Skorupa and Kemper34 reported that PGRMC1
exhibited an inhibitory effect on CYP3A4 drug metabolizing
activity by competitively binding with cytochrome P450 reductase
(CPR) in HEK293 or HepG2 cells. On the other hand,
Oda et al.42 reported that PGRMC1 had no effect to CYP2E1
and CYP3A4 activities in HepG2 cell. Several other groups
showed that PGRMC1 enhanced chemoresistance in several
cancer cells such as uterine sarcoma43, breast cancer17,
endometrial tumour13 and ovarian cancer44,45; however, no
evidence of PGRMC1-dependent regulation of CYP activity
was provided. Our results showed that PGRMC1 contributes
to enhancement of the doxorubicin metabolism, which is
mediated by CYP2D6 or CYP3A4 in human colon cancer


















































































































Figure 5 | Haem-dependent dimerization of PGRMC1 accelerates tumour growth through the EGFR signaling pathway. (a) Nucleotide sequences of
PGRMC1 targeted by shRNA and of the shRNA-resistant full length PGRMC1 expression vector. Stable PGRMC1-knockdown (PGRMC1-KD) HCT116 cells
were transiently transfected with the shRNA-resistant expression vector of wild-type PGRMC1 (wt) or the Y113F mutant (Y113F). (b) Erlotinib was added to
HCT116 (control) cells, PGRMC1-KD cells or PGRMC1-KD cells expressing shRNA-resistant PGRMC1 wt or Y113F, and cell viability was examined by MTT
assay. The data represent mean±s.d. of four separate experiments. *Po0.01 using ANOVA with Fischer’s LSD test. (c) Spheroid formation in control and
PGRMC1-KD HCT116 cells. Pictures indicate representative micrographs of spheroids formed under each condition. Spheroid size were measured and
compared among groups. The graph represents mean±s.e. of each spheroid size. *Po0.01 using ANOVA with Fischer’s LSD test. Scale bar: 0.1mm.
(d) Tumour-bearing livers of NOG mice at 10 days after intrasplenic injection of HCT116 (control) or PGRMC1-KD cells. Percentages of cross-sectional
areas showing metastatic tumours were calculated. Data represent mean±s.d. of 10 separate experiments. *Po0.05 using unpaired Student’s t-test.
Scale bar: 5mm.
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CYP family proteins and interactions with different xenobiotic
substrates should further be examined, the current results suggest
that the interaction of drug-metabolizing CYPs with the
haem-mediated dimer of PGRMC1 plays a crucial role in
regulating their activities.
We showed that haem-mediated dimerization of PGRMC1
enhances proliferation and chemoresistance of cancer cells
through binding to and regulating EGFR and cytochromes
P450 (illustrated in Fig. 7). Since the haem-binding afﬁnity of
PGRMC1 is lower than those of constitutive haem-binding
proteins such as myoglobin, PGMRC1 is probably interconverted
between apo-monomer and haem-bound dimer forms in
response to changes in the intracellular haem concentration.
Considering microenvironments in and around malignant
tumours, the haem concentration in cancer cells is likely to be
elevated through multiple mechanisms, such as (i) an increased
intake of haem, (ii) mutation of enzymes in TCA cycle (for
example, fumarate hydratase) that increases the level of succinyl
CoA, a substrate for haem biosynthesis and (iii) metastasis to
haem-rich organs such as liver, brain and bone marrow46–48.
Moreover, exposure of cancer cells to stimuli such as hypoxia,
radiation and chemotherapy causes cell damages and leads to
protein degradation, resulting in increased levels of TCA cycle
























































































































Figure 6 | Haem-dependent PGRMC1 dimerization enhances tumour chemoresistance through interaction with cytochromes P450.
(a,b) FLAG-PGRMC1 wild-type (wt) and Y113F mutant proteins (a.a.44–195), in either apo or haem-bound form, were incubated with CYP1A2
(a) or CYP3A4 (b) and immunoprecipitated with anti-FLAG antibody-conjugated beads. Input and bound proteins were detected by Western blotting.
(c) Binding assay was performed as in (a) using haem-bound FLAG-PGRMC1 wt and CYP1A2 with or without RuCl3 and CORM3. (d) Schematic illustration
of doxorubicin metabolism is shown on the left. Doxorubicin was incubated with HCT116 cells expressing control shRNA or shPGRMC1 (PGRMC1-KD),
and the doxorubicinol/doxorubicin ratios in cell pellets were determined using LC-MS. Data represent mean±s.d. of four separate experiments.
**Po0.01 versus control using unpaired Student’s t-test. (e) Indicated amounts of doxorubicin were added to HCT116 (control) cells, PGRMC1-KD cells,
or PGRMC1-KD cells expressing shRNA-resistant full-length PGRMC1 wt or Y113F, and cell viability was examined by MTT assay. Data represent
mean±s.d. of four separate experiments. *Po0.01 using ANOVA with Fischer’s LSD test.
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other hand, excessive haem induces HO-1, the enzyme that
oxidatively degrades haem and generates CO. Thus, HO-1
induction in cancer cells may inhibit the haem-mediated
dimerization of PGRMC1 through the production of CO and
thereby suppress tumour progression. This idea is consistent with
the observation that HO-1 induction or CO inhibits tumour
growth6,51.
Besides the regulatory roles of PGRMC1/Sigma-2 receptor in
proliferation and chemoresistance in cancer cells (ref. 52), recent
reports show that PGRMC1 is able to bind to amyloid beta
oligomer53 to enhance its neurotoxicity53,54. Furthermore, Sigma-
2 ligand-binding is decreased in transgenic amyloid beta
deposition model APP/PS1 female mice55. These results suggest
a possible involvement of PGRMC1 in Alzheimer’s disease. The
roles of haem-dependent dimerization of PGRMC1 in the
functional regulation of its target proteins deserve further
studies to ﬁnd evidence that therapeutic interventions to
interfere with the function of the dimer may control varied
disease conditions.
Methods
Materials. Recombinant EGF, CYP1A2 and CYP3A4 proteins were purchased
from Sigma. Erlotinib was purchased from Cayman. Doxorubicin was purchased
from Wako. Anti-FLAG (M2) antibody, FLAG peptide and anti-FLAG antibody-
conjugated agarose were purchased from Sigma. Haemin and protoporphyrin-IX
(PP-IX) were purchased from Porphyrin Science.
Plasmid constructions. Human PGRMC1 cDNA was cloned from the cDNA
library of HuH7 cells. The PGMRC1 (a.a.44–195 for in vitro studies and a.a.72–195
for crystallographic analyses and SV-AUC) cDNA fragment was ampliﬁed
with PCR, digested with Bam HI and Sal I and then ligated into pGEX6P-1
(GE Healthcare). For NMR analysis, the PGRMC1 (a.a.44–195) cDNA fragment
was ampliﬁed with PCR (with primers containing the factor Xa site) and ligated
into the Bam HI and Sal I sites of pGEX6P-1. The full-length PGRMC1 cDNA
fragment containing resistant sequences for shRNA was generated by using the
primers (Supplementary Methods), and ligated into the Eco RI and Bam HI sites
of the C-terminus of the 3xFLAG-tagged expression vector p3xFLAG CMV14
(Sigma).
Preparations of recombinant proteins. pGEX-PGRMC1 wt, Y113F or C129S
mutant expression vectors were transformed into BL21 (DE3), and the bacteria
were incubated in LB with ampicillin at 37 C until OD600 reached at 0.8. Protein
expression was induced by 1mmol l 1 isopropyl-b-thiogalactopyranoside for 4 h
at 37 C. Cell pellets were resuspended in the buffer containing 20mmol l 1
Tris-HCl (pH 7.5), 100mmol l 1 NaCl and 0.1% Tween 20, sonicated twice for
5min at 4 C and centrifuged at 20,000 g for 30min. The supernatant was
incubated with glutathione Sepharose 4B (GE Healthcare) for 1 h at 4 C. The resin
was then washed ﬁve times with the same buffer, and the GST tag was cleared by
addition of Precision Protease (GE Healthcare) and further incubation for 16 h at
4 C. The apo-PGRMC1 was prepared by eliminating the bacterial holo-PGRMC1
with size-exclusion chromatography (Superdex 200; GE Healthcare). Haem-bound
PGRMC1 were prepared by treatment with 100mmol l 1 haemin and puriﬁed by
size-exclusion chromatography. The PGRMC1 protein treated with Precision
Protease to cleave the GST-tag contained additional amino acid residues
(GPLGSEF) derived from the restriction site and the protease site for Precision
Protease at the N-terminal region of PGRMC1.
Isotope-labelled PGRMC1 proteins for NMR analyses were prepared by
growing cells (BL21 (DE3)) in minimal M9 media in H2O or 99.9% 2H2O,
including ampicillin, metals, vitamins, 15N-ammonium chloride and 13C or 12C
glucose as sources of nitrogen and carbon, respectively. These procedures were
followed by addition of 1mmol l 1 isopropyl-b-thiogalactopyranoside for 40 h at
20 C. Protein puriﬁcation was performed as mentioned above. The GST tag was
cleaved with Factor Xa (GE Healthcare). The proteins were treated with Factor
Xa to cleave the GST tag at the direct site of N-terminal region of PGRCM1
(a.a.44–195).
X-ray crystallography. PGRMC1 (a.a.72–195) crystals were grown at 20 C using
hanging-drop vapour diffusion by mixing equal volumes of protein solution
and reservoir solution containing 100mmol l 1 sodium cacodylate (pH 6.5)
and 1.26–1.45mol l 1 ammonium sulphate. Brown crystals reached maximum
size in three weeks. The crystals were soaked in reservoir solution containing 30%
trehalose and then ﬂash-frozen in liquid nitrogen. The X-ray diffraction data for
PGRMC1 crystals were collected at SPring-8 BL41XU and processed with XDS56.
The initial phase was obtained by single-wavelength anomalous dispersion, using a
dataset collected at 1.73 Å with PHENIX AutoSol57. Manual modeling and
reﬁnement were performed with COOT58 and phenix.reﬁne59. The deposited
model was reﬁned to a resolution of 1.95Å. In this model, 95.4% of the residues
were in favoured regions of Ramachandran plot, and all the others were in allowed
regions. Data collection and reﬁnement statistics are shown in Table 1. Molecular
ﬁgures were created by PyMOL (Schrodinger, LLC. The PyMOL Molecular
Graphics System, Version 1.5.0.3).
Mass spectrometry analyses. The puriﬁed PGRMC1 (a.a.44–195) proteins, the
wild-type (apo and haem) and the C129S mutant (apo and haem), which included
additional amino acid residues (GPLGSEF), were buffer-exchanged into
100mmol l 1 ammonium acetate, pH 7.5, by passing the proteins through a
Bio-Spin 6 column (Bio-Rad). The buffer-exchanged PGRMC1 wild-type (apo and
haem) and PGMRC1 C129S mutants were immediately analysed by nanoﬂow
electrospray ionization MS using gold-coated glass capillaries made in house. In the
case of ESI-MS analyses under denaturing conditions, buffer-exchanged proteins
were denatured before ESI-MS analyses by adding aliquots of formic acid at ﬁnal
concentration of 30%). Spectra were recorded on a SYNAPT G2 HDMS mass
spectrometer (Waters, Manchester, UK) in positive ionization mode at 1.20 kV
with a 120V sampling cone voltage. The spectra were calibrated using 1mgml 1
caesium iodide and analysed with Mass Lynx software (Waters).
SV-AUC analyses. SV-AUC experiments were performed in a ProteomeLab XL-I
analytical ultracentrifuge (Beckman Coulter) equipped with 4-hole An60Ti rotors
at 20 C using Beckman Coulter 12-mm double-sector aluminium centerpieces and
sapphire windows. Recombinant PGRMC1 proteins were diluted with the buffer
(20mmol l 1 Tris-HCl (pH 7.5) and 100mmol l 1 NaCl) at the indicated
concentration. Scanning was performed as quickly as possible at 262,080 g at 6.5 cm
(60,000 rpm), between 6.0 and 7.2 cm from the axis of rotation with a radial
increment of 30mm using an absorbance optical system. The sedimentation
coefﬁcient distributions were obtained using the c(s) method of SEDFIT60. The
partial speciﬁc volume, buffer density and viscosity were calculated using the
program SEDNTERP 1.09 and were 0.7216 cm3 g 1, 1.00293 gml 1, and 1.017 cP,
respectively. The sedimentation coefﬁcient of PGRMC1 (a.a.72–195) was calculated
with the UltraScan Solution Modeler (US-SOMO) suite61 using the crystal
structure determined in this study. To analyse the effect of CO, protein samples
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Figure 7 | Schematic diagram for the regulation of PGRMC1 functions.
Apo-PGRMC1 exists as an inactive monomer. On binding to haem, PGRMC1
forms a dimer through stacking interactions between the haem moieties,
which enables PGRMC1 to interact with EGFR and cytochromes P450,
leading to an enhanced proliferation and chemoresistance of cancer cells.
CO interferes with the stacking interactions of the haems and thereby
inhibits PGRMC1 functions.
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DOSY analysis. Diffusion-ordered 2D NMR spectroscopy (DOSY) was used to
investigate the oligomerization state of PGRMC1 (a.a.44–195) induced by haem
binding. Apo- or haem-bound PGRMC1 and reference proteins (including hen
egg lysozyme, ovalbumin and bovine serum albumin (BSA)) dissolved in
50mmol l 1 phosphate buffer (pH 7.0) containing 5% D2O were measured at
25 C. The protein concentrations were 0.15–0.2mmol l 1. DOSY spectra were
measured using the stimulated echo sequence with a longitudinal-eddy-current
delay62,63, and diffusion coefﬁcients were calculated from signals in the aliphatic
regions using the software TOPSPIN (Bruker). The signal intensities ﬁt the
Stejskal-Tanner equation:
I=I 0ð Þ ¼ e g2g2d2 D d3ð ÞD
where I represents the signal intensity when gradient pulses of length d are
applied at strength g, varying from 2 to 95% of the full gradient strength
(55G cm 1). The diffusion coefﬁcient D25 is estimated by curve ﬁtting with the
term I(0), which corresponds to the signal intensity at a gradient strength of 0. The
term g represents the gyromagnetic ratio, and D represents the delay between two
sets of gradients responsible for the stimulated echo. In this study, d was set to 8 or
10ms, and D was set to 40ms. The hydrodynamic radii of the proteins were
estimated on the basis of the Stokes–Einstein equation as follows:
D ¼ kBT
6pZr
where T is the absolute temperature, r is the hydrodynamic radius of the spherical
molecule, Z is the viscosity of the solvent, and kB is the Boltzmann constant. The
molecular weights (MWs) of apo- and haem-bound PGRMC1 proteins were
estimated from a relationship between r and MWs. MWs of apo and haem-bound
PGRMC1 proteins were obtained from the linear-ﬁtting of measured r values for
the reference proteins with known MWs according to the following equation:
MW¼ 1.2864 (r3)þ 8.0411.
UV-visible absorption spectrometry and haem titration analysis. UV-visible
absorption spectra of the protein were recorded with a V-660 (Jasco) spectro-
photometer at room temperature. Haem binding was tracked by difference
spectroscopy in the Soret region of the UV-visible spectrum. Successive aliquots
of 0.5mmol l 1 haemin in N,N-dimethylformamide were added to both the
sample cuvette, which contained 10 mmol l 1 apo-PGRMC1 (a.a.44–195), and the
reference cuvette. Spectra were recorded 3min after the addition of each haem
aliquot. The absorbance difference at 400 nm was plotted as a function of haem
concentration, and the dissociation constant (Kd) was calculated using a quadratic
binding equation.
Gel ﬁltration chromatography. Recombinant PGRMC1 (a.a.44–195) (10 mg) wt,
Y113F or C129S mutant, treated with 5mmol l 1 sodium dithionite and/or CO gas
or left untreated, was separated on a Superdex 200 column equilibrated in buffer
containing 20mmol l 1 Tris-HCl (pH 7.5) and 100mmol l 1 NaCl using a
SMART system (GE Healthcare). To prepare the reducing conditions for ferrous
haem proteins, the running buffer was deaerated by boiling and saturating it
with argon gas according to modiﬁed versions of previously reported methods64,65.
Namely, immediately after adding dithionite to give a ﬁnal concentration of
5mmol l 1, the buffer was equilibrated into the column. The SMART system was
sealed with gas-tight taping to maintain anaerobic conditions. Separations of
proteins were completed within 1 h. Protein samples were also prepared in the
deaerated solution and treated with dithionite at 5mmol l 1 and/or CO gas, right
before being injected into the column. Fractions were then subjected to SDS-PAGE
under ambient conditions and visualized by silver staining. The size of proteins was
estimated using molecular mass markers (thyroglobin, 669 kDa; catalase, 232 kDa;
aldolase, 150 kDa; bovine albumin, 66 kDa and b-amylase, 20 kDa). Results
showing that the molecular size of PGRMC1 became smaller in CO-treated
conditions (Fig. 3) were collected B60min after the start of experiments. The
stability of CO-binding to PGRMC1 was examined with UV-visible absorption
spectra to chase temporal alterations for 2 h, as shown in Supplementary Fig. 14.
In vitro binding assays. For in vitro binding assays, EGFR protein was obtained
from ENZO (BML-SE116) as full length protein isolated from human A431 cells.
Human CYP1A2, CYP3A4 proteins puriﬁed as a microsomal formulation
containing cytochrome b5 and cytochrome P450 reductase were obtained from
Sigma (C1561 and C4982, respectively). Proteins for human CYP1A2, CYP3A4 or
EGFR (1 mg) were incubated with 10mg of FLAG-PGRMC1 (a.a.44–195) treated
with or without 50 mmol l 1 haemin in 500 ml of binding buffer containing
20mmol l 1 HEPES-NaOH (pH 7.9), 100mmol l 1 NaCl, 0.2mmol l 1 EDTA,
10% glycerol and 0.1% NP40 for 60min at room temperature. 5mmol l 1 sodium
dithionite was added to produce the reducing conditions speciﬁed in the
aforementioned methods, and the effects of CORM3 or RuCl3 at 10mmol l 1 were
examined. Then, 10 ml of equilibrated anti-FLAG (M2) agarose was added to the
mixture, which was then incubated for 60min at room temperature. Bound
proteins were washed three times with 200 ml of binding buffer and eluted with
10ml of 2 mgml 1 FLAG peptide. The eluates were subjected to SDS-PAGE
and visualized by Western blotting using antibodies against CYP1A2, CYP3A4
(Santa Cruz: sc-30085 and sc-53850, respectively), FLAG and EGFR (Cell signaling:
#2232S).
Cell culture analyses. The human colon cancer cell line HCT116 and human
hepatoma cell line HuH7 were maintained in DMEM medium containing 10%
FCS. To generate a stable PGRMC1 knockdown cell line, lentivirus vectors
encoding a control or PGRMC1 targeting shRNA sequence were transfected into
293FT cells. The lentivirus was prepared according to the manufacturer’s
instructions (Invitrogen). HCT116 and HuH7 cells were infected with the
lentivirus, and a stable cell line was selected by maintaining the cells in medium
containing 10 mgml 1 blasticidin (Invitrogen) for 1 week.
For co-immunoprecipitation assay, the expression vector of FLAG-PGRMC1 or
an empty vector into HCT116 by using a transfection reagent Lipofectamine 2000
(Invitrogen). Cells were incubated with or without 250m mol l 1 succinylacetone
(SA) for 48 h, and the cells were then lysed with NP40 lysis buffer (20mmol l 1
Tris-HCl (pH 7.5), 150mmol l 1 NaCl, 1% NP40). The lysates were incubated
with 10ml of equilibrated anti-FLAG (M2) agarose for 60min at room temperature.
Bound proteins were washed three times, and were subjected to SDS-PAGE and
visualized by Western blotting using antibodies against PGRMC1 (NOVUS:
NBP1–83220) and EGFR.
For analysis of EGFR signaling, cells were incubated overnight with serum-
deprived medium, and then 100 ngml 1 EGF was added for 5min. Cells were
lysed with RIPA buffer, and the lysates were subjected to SDS-PAGE and visualized
by Western blotting using antibodies against PGRMC1, EGFR, phospho-Y1068
EGFR (Cell signaling: #2234S), AKT (Cell signaling: #9272S), phospho-S473AKT
(Cell signaling: #4060S), ERK (Cell signaling: #4695S) and phospho-T185 Y187
ERK (Invitrogen: 44680G).
To analyse proliferation of HCT116 cells, Lipofectamine 2000 (Invitrogen) was
used to transfect the shRNA-resistant expression vector of FLAG-PGRMC1 or an
empty vector into HCT116 control or PGRMC1-knockdown cells. After 24 h, the
cells were seeded and incubated for 12 h on a 96-well plate, after which erlotinib or
doxorubicin was added for 24 h. Cell viability was determined by using an MTT
assay kit (Millipore) according to the manufacturer’s instructions.
For analysis of spheroid formation of HCT116 cells, the shRNA-resistant
expression vector of FLAG-PGRMC1 or an empty vector was transfected as
described above. After 24 h, cells were seeded at 1 104 cells per well onto a
96-well spheroid culture plate (NanoCulture plate with a microsquare pattern,
SCIVAX Corp.) and incubated for three days. The size of individual spheroid was
determined by measuring their optical areas using Image-J and by calculating the
apparent radius (r) to estimate their apparent volume (v) according to the
following formula: v¼ 4/3pr3.
Measurements of intracellular haem concentrations. To measure protohaem
(haem b) concentrations, LC-UV and LC-MS analyses were performed for
quantiﬁcation and molecular identiﬁcation, respectively. Brieﬂy, HCT116 cells
(1 107 cells) were treated with vehicle or 250 mmol l 1 SA for 48 h. After
centrifugation, haem b was extracted from cell pellets twice by adding acetone
containing 30% formate, followed by a 5min sonication and centrifugation. The
supernatant was collected, and the solvent was evaporated. The dried residues were
re-dissolved in acetonitrile containing 0.2% formate and subjected to a LCMS-8030
system equipped with photodiode array (PDA) detector (SPD-20A) (Shimadzu
Corporation, Kyoto, Japan). Haem b was detected by monitoring the absorption at
400 nm. Its identity was conﬁrmed by simultaneous mass spectrometric analysis
at m/z 616.
Analyses of doxorubicin metabolism. HCT116 cells (5 106 cells/10 cm dish)
were cultured for 2 days, after which the cells were cultured in the presence of
0.3 mmol l 1 doxorubicin overnight. The cells were lysed with methanol containing
internal standard compounds, and then water-soluble fraction was separated by
liquid-liquid extraction (chloroform: methanol: water¼ 1: 2: 1). The amounts
of doxorubicin and its metabolites were quantiﬁed using LC-MS/MS. Brieﬂy,
a triple-quadrupole mass spectrometer equipped with an electrospray ionization
(ESI) ion source (LCMS-8030; Shimadzu Corporation) was used in the positive-ESI
and multiple reaction monitoring modes. The samples were resolved on an
ACQUITY UPLC BEH C18 column (100 2.1mm i.d., 1.7 mm particle) using
water and acetonitrile as mobile phases A and B, respectively, at a ﬂow rate of
0.15mlmin 1 and a column temperature of 40 C. Ion transitions from m/z 544 to
m/z 130 and from m/z 546 to m/z 399 for doxorubicin and doxorubicinol,
respectively, were monitored for their quantiﬁcation.
Xenograft implantation of HCT116 cells. All the protocols for animal
experiments in this study were approved by the Experimental Animal Committee
of Keio University School of Medicine (the approved number; 08037-(7)). A model
of liver metastases of human colon cancer was prepared according to our previous
methods with minor modiﬁcations7,30. Brieﬂy, HCT116 cells transfected with the
cDNA of Venus (1 106 cells/mice), a highly sensitive ﬂuorescent protein on tissue
slice sections,66 were transplanted into the spleens of 10-week-old male NOG mice.
Ten days after transplantation, the animals were anesthetized with sevoﬂurane
(Maruishi Pharmaceutical), and their livers were removed, embedded in super-
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cryoembedding medium and frozen quickly in liquid nitrogen. The frozen tissues
were sliced with a cryostat (Leica CM1900) at a thickness of 5 mm, and
haematoxylin-eosin staining was performed. Fluorescent microscopy (Keyence:
BIOREVO, BZ-9000) was used to observe Venus ﬂuorescence. Percentages of
cross-sectional areas showing metastatic tumours were calculated by Image-J
as previously described7.
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